Dr Sanders receives grants or honoraria funds from Boston Scientific, Abbott Medical, Becton Dickenson, Pacemate, and CathRx. Dr Natale receives consultation funds from Abbott Medical, Baylis, Biosense Webster, Biotronik, and Boston Scientific. Dr Kuck receives consultation funds from Cardiovalve. Dr Boersma receives consultation funds from Boston Scientific, Abbott Medical, Adagio Medical, Acutus Medical, and Philips Medical. Dr Sood receives consultation or honoraria funds from Johnson & Johnson, Boston Scientific, Atricure, Bristol Myers, and Pfizer. Dr Marchlinski receives grants, consultation, or honoraria funds from Biosense Webster, Abbott Medical, and Biotronik. Dr De Lurgio receives consultation or honoraria funds from Atricure and Boston Scientific. Dr Verma receives grants or consultation funds from Biosense Webster, Bayer, Medlumics, Adagio Medical, and Boston Scientific. Cerkvenik are employees of Medtronic, Inc. PULSED AF demonstrated a low rate of primary safety adverse events (0.7%) and provided effectiveness consistent with established ablation technologies using a novel irreversible electroporation energy to treat patients with AF.Ītrial fibrillation catheter ablation clinical trial electroporation pulsed field ablation.ĭisclosures Drs Verma, Boersma, Calkins, Haines, Hindricks, Kuck, Marchlinski, Natale, Packer, De Lurgio, and Sanders receive consultation funds from Medtronic, Inc. The primary safety end point occurred in 1 patient (0.7% 95% CI, 0.1 to 4.6) in both the paroxysmal and persistent AF cohorts. Pulsed field ablation was shown to be effective at 1 year in 66.2% (95% CI, 57.9 to 73.2) of patients with paroxysmal AF and 55.1% (95% CI, 46.7 to 62.7) of patients with persistent AF. Kaplan-Meier methods were used to evaluate the primary end points. The primary safety end point was freedom from a composite of serious procedure- and device-related adverse events. The primary effectiveness end point was freedom from a composite of acute procedural failure, arrhythmia recurrence, or antiarrhythmic escalation through 12 months, excluding a 3-month blanking period to allow recovery from the procedure. All patients were monitored for 1 year using weekly and symptomatic transtelephonic monitoring 3-, 6-, and 12-month ECGs and 6- and 12-month 24-hour Holter monitoring. The PULSED AF pivotal study (Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF) was a prospective, global, multicenter, nonrandomized, paired single-arm study in which patients with paroxysmal (n=150) or persistent (n=150) symptomatic atrial fibrillation (AF) refractory to class I or III antiarrhythmic drugs were treated with pulsed field ablation. Pulsed field ablation may have effectiveness comparable to traditional catheter ablation while preventing thermally mediated complications. 2007 8:288–291.Pulsed field ablation uses electrical pulses to cause nonthermal irreversible electroporation and induce cardiac cell death. Prominent crista terminalis and Eustachian ridge in the right atrium: Two dimensional (2D) and three dimensional (3D) imaging. Relevance to catheter ablation of the septal isthmus and a new technique for rapid identification of ablation success. Role of the tricuspid annulus and the eustachian valve/ridge on atrial flutter. Electrophysiological anatomy of typical atrial flutter: the posterior boundary and causes for difficulty with ablation. Correlative anatomy and electrophysiology for the interventional electrophysiologist: right atrial flutter. The inferior right atrial isthmus: further architectural insights for current and coming ablation technologies. Cabrera J.A., Sanchez-Quintana D., Farre J., Rubio J.M., Ho S.Y.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |